However, bevacizumab—an anti-VEGF antibody that can control edema—failed to improve OS in GBM patients under ICB therapy (1, 21), suggesting a VEGF-independent mechanism for ICB-induced edema. This evidence concerns the gene VEGFA and glioblastoma.